146 related articles for article (PubMed ID: 35512420)
21. CDDO-Me protects normal lung and breast epithelial cells but not cancer cells from radiation.
El-Ashmawy M; Delgado O; Cardentey A; Wright WE; Shay JW
PLoS One; 2014; 9(12):e115600. PubMed ID: 25536195
[TBL] [Abstract][Full Text] [Related]
22. CDDO-Me Inhibits Microglial Activation and Monocyte Infiltration by Abrogating NFκB- and p38 MAPK-Mediated Signaling Pathways Following Status Epilepticus.
Kim JE; Park H; Lee JE; Kang TC
Cells; 2020 May; 9(5):. PubMed ID: 32370011
[TBL] [Abstract][Full Text] [Related]
23. CDDO-imidazolide Targets Multiple Amino Acid Residues on the Nrf2 Adaptor, Keap1.
Meng X; Waddington JC; Tailor A; Lister A; Hamlett J; Berry N; Park BK; Sporn MB
J Med Chem; 2020 Sep; 63(17):9965-9976. PubMed ID: 32787104
[TBL] [Abstract][Full Text] [Related]
24. Bardoxolone ameliorates TGF-β1-associated renal fibrosis through Nrf2/Smad7 elevation.
Song MK; Lee JH; Ryoo IG; Lee SH; Ku SK; Kwak MK
Free Radic Biol Med; 2019 Jul; 138():33-42. PubMed ID: 31059771
[TBL] [Abstract][Full Text] [Related]
25. Location, Orientation and Aggregation of Bardoxolone-ME, CDDO-ME, in a Complex Phospholipid Bilayer Membrane.
Galiano V; Encinar JA; Villalaín J
J Membr Biol; 2020 Apr; 253(2):115-128. PubMed ID: 31965219
[TBL] [Abstract][Full Text] [Related]
26. Prevention of murine lupus nephritis by targeting multiple signaling axes and oxidative stress using a synthetic triterpenoid.
Wu T; Ye Y; Min SY; Zhu J; Khobahy E; Zhou J; Yan M; Hemachandran S; Pathak S; Zhou XJ; Andreeff M; Mohan C
Arthritis Rheumatol; 2014 Nov; 66(11):3129-39. PubMed ID: 25047252
[TBL] [Abstract][Full Text] [Related]
27. Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils.
Thimmulappa RK; Fuchs RJ; Malhotra D; Scollick C; Traore K; Bream JH; Trush MA; Liby KT; Sporn MB; Kensler TW; Biswal S
Antioxid Redox Signal; 2007 Nov; 9(11):1963-70. PubMed ID: 17822364
[TBL] [Abstract][Full Text] [Related]
28. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells.
Shishodia S; Sethi G; Konopleva M; Andreeff M; Aggarwal BB
Clin Cancer Res; 2006 Mar; 12(6):1828-38. PubMed ID: 16551868
[TBL] [Abstract][Full Text] [Related]
29. CDDO-me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cells.
Deeb D; Gao X; Dulchavsky SA; Gautam SC
Anticancer Res; 2007; 27(5A):3035-44. PubMed ID: 17970042
[TBL] [Abstract][Full Text] [Related]
30. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells.
Zou W; Liu X; Yue P; Zhou Z; Sporn MB; Lotan R; Khuri FR; Sun SY
Cancer Res; 2004 Oct; 64(20):7570-8. PubMed ID: 15492284
[TBL] [Abstract][Full Text] [Related]
31. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179.
Ahmad R; Raina D; Meyer C; Kharbanda S; Kufe D
J Biol Chem; 2006 Nov; 281(47):35764-9. PubMed ID: 16998237
[TBL] [Abstract][Full Text] [Related]
32. Oleanane triterpenoid CDDO-Me inhibits Akt activity without affecting PDK1 kinase or PP2A phosphatase activity in cancer cells.
Liu Y; Gao X; Deeb D; Gautam SC
Biochem Biophys Res Commun; 2012 Jan; 417(1):570-5. PubMed ID: 22177954
[TBL] [Abstract][Full Text] [Related]
33. The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent.
Vannini N; Lorusso G; Cammarota R; Barberis M; Noonan DM; Sporn MB; Albini A
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3139-46. PubMed ID: 18065492
[TBL] [Abstract][Full Text] [Related]
34. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice.
Yates MS; Tran QT; Dolan PM; Osburn WO; Shin S; McCulloch CC; Silkworth JB; Taguchi K; Yamamoto M; Williams CR; Liby KT; Sporn MB; Sutter TR; Kensler TW
Carcinogenesis; 2009 Jun; 30(6):1024-31. PubMed ID: 19386581
[TBL] [Abstract][Full Text] [Related]
35. CDDO-Me reveals USP7 as a novel target in ovarian cancer cells.
Qin D; Wang W; Lei H; Luo H; Cai H; Tang C; Wu Y; Wang Y; Jin J; Xiao W; Wang T; Ma C; Xu H; Zhang J; Gao F; Wu YL
Oncotarget; 2016 Nov; 7(47):77096-77109. PubMed ID: 27780924
[TBL] [Abstract][Full Text] [Related]
36. ROS mediate proapoptotic and antisurvival activity of oleanane triterpenoid CDDO-Me in ovarian cancer cells.
Gao X; Liu Y; Deeb D; Liu P; Liu A; Arbab AS; Gautam SC
Anticancer Res; 2013 Jan; 33(1):215-21. PubMed ID: 23267148
[TBL] [Abstract][Full Text] [Related]
37. CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells.
Deeb D; Gao X; Dulchavsky SA; Gautam SC
J Exp Ther Oncol; 2008; 7(1):31-9. PubMed ID: 18472640
[TBL] [Abstract][Full Text] [Related]
38. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.
Lu MC; Ji JA; Jiang ZY; You QD
Med Res Rev; 2016 Sep; 36(5):924-63. PubMed ID: 27192495
[TBL] [Abstract][Full Text] [Related]
39. Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-kappaB and Notch1 signaling.
Gao X; Deeb D; Jiang H; Liu Y; Dulchavsky SA; Gautam SC
J Neurooncol; 2007 Sep; 84(2):147-57. PubMed ID: 17361329
[TBL] [Abstract][Full Text] [Related]
40. The Triterpenoid Nrf2 Activator, CDDO-Me, Decreases Neutrophil Senescence in a Murine Model of Joint Damage.
Amirova KM; Dimitrova PA; Leseva MN; Koycheva IK; Dinkova-Kostova AT; Georgiev MI
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
